Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (171-180 of 446) with videos related to

Pageof 45
Sort By:
Leukemia|October 29, 2011
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategiesS Sinha, M A Gertz, M Q Lacy, et al.
American Journal of Hematology|October 1, 2011
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myelomaGuner Hayri Ozsan, Ivana N Micallef, Angela Dispenzieri, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 14, 2018
Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?Eli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Blood|July 19, 2013
Implications of continued response after autologous stem cell transplantation for multiple myelomaWilson I Gonsalves, Morie A Gertz, Angela Dispenzieri, et al.
Haematologica|June 5, 2013
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Nelson Leung, Siobhan V Glavey, Shaji Kumar, et al.
Leukemia|May 8, 2013
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myelomaG Srivastava, V Rana, M Q Lacy, et al.
Bone Marrow Transplantation|June 14, 2019
The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myelomaKevin C Miller, Morie A Gertz, Francis K Buadi, et al.
Leukemia|August 30, 2017
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantationR Chakraborty, E Muchtar, S K Kumar, et al.
Bone Marrow Transplantation|August 18, 2018
Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myelomaKevin C Miller, Morie A Gertz, Francis K Buadi, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Pageof 45

Showing results (171-180 of 446) with videos related to

Sort By:
Pageof 45
Leukemia|October 29, 2011
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategiesS Sinha, M A Gertz, M Q Lacy, et al.
American Journal of Hematology|October 1, 2011
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myelomaGuner Hayri Ozsan, Ivana N Micallef, Angela Dispenzieri, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|March 14, 2018
Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?Eli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Blood|July 19, 2013
Implications of continued response after autologous stem cell transplantation for multiple myelomaWilson I Gonsalves, Morie A Gertz, Angela Dispenzieri, et al.
Haematologica|June 5, 2013
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Nelson Leung, Siobhan V Glavey, Shaji Kumar, et al.
Leukemia|May 8, 2013
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myelomaG Srivastava, V Rana, M Q Lacy, et al.
Bone Marrow Transplantation|June 14, 2019
The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myelomaKevin C Miller, Morie A Gertz, Francis K Buadi, et al.
Leukemia|August 30, 2017
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantationR Chakraborty, E Muchtar, S K Kumar, et al.
Bone Marrow Transplantation|August 18, 2018
Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myelomaKevin C Miller, Morie A Gertz, Francis K Buadi, et al.
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Pageof 45